The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thoth2.
Did you ever frequent the James Joyce Pub in the Pelikanstraase.
In Winter great bowls of kartoffelsuppe mit crevetten with a large glass of port went down very well
Cheers pal.
Love those kind of stories. Life enhancing and unforgettable stuff.
We shall share more at “THE party”!!
Look after yourself.
Peff
Peff. For nearly 8 years i commuted to zurich. Had my circle of bars hotels etc i used. One week i flew out. Couldnt get a hotel. Davos or something was on. I retired to my fav bar (safari bar. Niededorf). Where i was good friends with the landlady and whinged whilst trying to find a hotel. She suggested staying with a hooker friend and linked us up. Half the price of a hotel. Central location. The girl got a 2 week sex free holiday. And did all my laundry for free. I got to live in an 80 room brothel for less than a hotel. Was an interesting 2 weeks. Just watching what went on in the streets outside. Long time ago now.
There is a an attachment below which you may find interesting which relates to Sierra's Momelotinib. It does look promising for them, which must be good for not only them of course, but us too.. 6 months before results expected to come through ie ist quarter of 2022.
http://www.sierraoncology.com/wp-content/uploads/2021/06/2021.06.02-SRRA-Corp-Presentation.pdf
Nothing wrong with critical thinking Steadydanny. There is just so much, we do not know, or have not been supplied all or the correct information.
Regards
Peff
Think you may have just got yourself an invite with that posting - as Simon Cowell would say it’s a yes from me but then again it’s not my party - very funny!
GLA
Thoth2, as you know I’m a whole hearted disciple. Never met you, probably never will (unless there’s a £45per share party). I’ve put my full trust (and 500k of shares) in your hands and am following your guidance (based on your track record that I’ve observed over quite a few years now). Its my choice and I will never hold you accountable if anything (very unlikely) goes nipples vertical.
However, what I’m really intrigued by is that period when you lived in a brothel!!!!
Please elaborate and expand on this.
C’mon SAR
Have a great weekend and beyond everyone.
Sorry for this ****e but had a touch of the celebratory weekend sauce I’m afraid!!??
SOG I'm glad you used the term MF. I wanted to discuss that point but my spelling is carp. In my camp I'm thinking issues with blood platelets being interfered with. Hence cytokine storms and now 3 countries reporting spike proteins moving to organs from the injection point. Appreciate we may be on a different hymn sheet here. But the whole lupus program and military games in China August 2019, then my missus close to hospitization visiting relatives December 2019 in HK..with a flu type scenario.
I consider my self a critical thinker.
Thankyou SOG. Also I find it interesting have confirmed they have acquired the numbers of individuals for their Momentum programme.
Also on a personal note re you getting trolled today. There are some real a holes out there who hate a reality check and when challenged they resort to personal attacks.
It shows they can't communicate with a demeanor that is intelligent and able of critical thinking.
Always like your posts. Sound words. When you briefly left I felt the Sareum unfolding story lost a fantastic acolyte.
So glad you are back. Don't let the bar stewards get you down.
Best regards Steadydanny
Certainly food for thought there Steadydanny.
SRA has a fantastic pedigree. Developed alongside ICR and much to do with Michelle Garrett.
An abstract from June 2017:-
Sierra Oncology Reports Encouraging Initial Progress from Ongoing Phase 1 Clinical Trials.
Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, notes an announcement made today by Sierra Oncology, Inc. reporting on the initial progress of the two ongoing Phase 1 trials of the Chk1 inhibitor, SRA737. The full announcement can be found on Sierra Oncology's IR website*.
This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014.
The SRA737 Phase 1 monotherapy trial has advanced through six single patient dose cohorts of 20, 40, 80, 160, 300 and 600 mg/day, administered under a continuous daily oral dosing regimen in 28-day cycles. Dose escalation will continue until a maximum tolerated dose (MTD) is reached, in parallel with ongoing Cohort Expansion enrolment.
Preliminary observations from the ongoing monotherapy study are as follows:
• SRA737 has been very well-tolerated to date: No Grade 2 or higher SRA737-related adverse events have been reported. No dose-limiting toxicities have been observed and an MTD has not been reached.
Note the ' no dose limiting toxicities have been observed' and maximum tolerated dose not been reached.
From 2018 :-
SRA737 Combination with Immuno-Oncology
During its Program Update in February, Sierra presented preclinical data providing evidence of synergy between SRA737 and immune checkpoint blockade. Sierra is currently designing a clinical study for this combination, which potentially could be submitted to regulatory authorities in the fourth quarter of 2018.
Interesting this Immuno- Oncology.
Interesting also is our CHK1 with regards to treatment of HGSOC ( high grade serious ovarian cancer)
see the link
https://www.prnewswire.com/news-releases/sierra-oncology-reports-preclinical-efficacy-for-chk1-inhibitor-sra737-in-treatment-refractory-ovarian-cancer-models-at-the-eortc-nci-aacr-symposium-300750660.html
All very impressive and lack of development has caused us to forget just how ' more commercially viable' SRA737 is.
I am thinking the stars are aligning for a deal of some sort to progress SRA737. If they do not use it they lose it along with a whole heap of costly research and investment.
Into August next week and the clock is ticking very fast. Deals are not done overnight. Plans in whatever shape of form will be in progress now ( my uptake of situation). I would estimate on commencement of development and trials, circa 100 million at least on market cap circa 3p per share increase. The market is huge and much left untouched with no competitors.
There is just so much potential in combo therapy with CHK1.
Regards
You ramble away mate very interesting thoughts and always good to look at another possible angle.Another good week and hopefully another good month ahead
GLA
Come on the SAR
Come o
Appreciate any feedback. Please be kind. I'm no scientist but do have an understanding of DNA and RNA and cytokine storms and cytotoxicity.
So in a nut shell our RNS today re a further US Patent application, of which I see on Sareums website there is a direct link to all patent applications and progress and approvals including China, Japan and parts of Europe.
Makes for good reading.
Then I see the Sierra TM application discussed today that effectively as I read here was a bit of jiggery pokery with their trading name fonts.
So we are are awaiting 737 updates and I then look at Sierras financial position and the last thing I thought they would do is spend money they don't (yet) have on a corporate image logo update.
So if you were going to a ball wouldn't you want to be seen with your best updated image?
Is it a coincidence?
Also enter HNWIs!
It is something in my gut (re our 12 November 2020 RNS aboutSRA737 suggestion of broader applications ...) that really makes me think something is definitely being carefully and diligently rolled out.
Please ignore if I am rambling without a noteable point, or politely just say I'm off the mark.
Best regards Steadydanny